Products
Relatlimab Biosimilar Monoclonal Antibody (LAG-3) for Research
Pre-Made Relatlimab biosimilar, Whole mAb, Anti-LAG3 Antibody: Anti-CD223 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Relatlimab (INN; development code BMS-986016) is a monoclonal antibody designed for the treatment of melanoma.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-476-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Relatlimab biosimilar, Whole mAb, Anti-LAG3 Antibody: Anti-CD223 therapeutic antibody |
| INN Name | Relatlimab |
| Target | LAG3 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II/III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Bristol-Myers Squibb;Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Conditions Approved | na |
| Conditions Active | Malignant melanoma;Colorectal cancer;Gastric cancer;Renal cell carcinoma;Solid tumours;Oesophageal cancer;Glioblastoma |
| Conditions Discontinued | Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Hodgkin's disease;Mantle-cell lymphoma;Non-Hodgkin's lymphoma |
| Development Tech | na |
About target - LAG3
1. Protein Lymphocyte activation gene 3 protein
2. Gene LAG3
3. Organism Homo sapiens (Human)
Function
Lymphocyte activation gene 3 protein: Inhibitory receptor on antigen activated T-cells (PubMed:7805750, PubMed:8647185, PubMed:20421648).
Delivers inhibitory signals upon binding to ligands, such as FGL1 (By similarity).
FGL1 constitutes a major ligand of LAG3 and is responsible for LAG3 T-cell inhibitory function (By similarity).
Following TCR engagement, LAG3 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity).
May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1, possibly by acting as a coreceptor for PDCD1/PD-1 (By similarity).
Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8+ and CD4+ T-cells (PubMed:7805750, PubMed:8647185, PubMed:20421648).
Also mediates immune tolerance: constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function (By similarity).
Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation (By similarity).
Binds MHC class II (MHC-II); the precise role of MHC-II-binding is however unclear (PubMed:8647185).
Secreted lymphocyte activation gene 3 protein:
May function as a ligand for MHC class II (MHC-II) on antigen-presenting cells (APC), promoting APC activation/maturation and driving Th1 immune response.
